Abstract | PURPOSE: PATIENTS AND METHODS: RESULTS: One hundred twenty-nine patients were evaluable for efficacy (FG, n = 41; oral iron, n = 44; no iron, n = 44). Mean increase in Hb was 2.4 g/dl (95% confidence interval [CI], 2.1-2.7) for FG (p = .0092 vs. oral iron; p = .0044 vs. no iron), 1.6 g/dl (95% CI, 1.1-2.1) for oral iron (p =.7695 vs. no iron), and 1.5 g/dl (95% CI, 1.1-1.9) for no iron. Hb response (increase > or =2 g/dl) was 73% for FG (p = .0099 vs. oral iron; p = .0029 vs. no iron), 46% for oral iron (p = .6687 vs. no iron), and 41% for no iron. FG was well tolerated. CONCLUSION: For cancer patients with chemotherapy-related anemia receiving epoetin alfa, FG produces a significantly greater increase in Hb and Hb response compared with oral iron or no iron, supporting more aggressive treatment with IV iron supplementation for these patients.
|
Authors | David H Henry, Naomi V Dahl, Michael Auerbach, Simon Tchekmedyian, Leslie R Laufman |
Journal | The oncologist
(Oncologist)
Vol. 12
Issue 2
Pg. 231-42
(Feb 2007)
ISSN: 1083-7159 [Print] England |
PMID | 17296819
(Publication Type: Journal Article, Multicenter Study, Randomized Controlled Trial, Research Support, Non-U.S. Gov't)
|
Chemical References |
- Antineoplastic Agents
- Ferric Compounds
- Hematinics
- Recombinant Proteins
- Erythropoietin
- Epoetin Alfa
- Iron
- ferric gluconate
|
Topics |
- Administration, Oral
- Aged
- Anemia
(blood, chemically induced, drug therapy)
- Antineoplastic Agents
(adverse effects)
- Epoetin Alfa
- Erythropoietin
(therapeutic use)
- Female
- Ferric Compounds
(administration & dosage)
- Hematinics
(administration & dosage)
- Humans
- Iron
(administration & dosage)
- Male
- Middle Aged
- Neoplasms
(blood, complications)
- Prospective Studies
- Recombinant Proteins
|